Trial Profile
A Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Noninferiority Study Comparing 75mg Risedronate Dosed on 2 Consecutive Days Monthly With 5mg Daily Risedronate in the Treatment of Postmenopausal Osteoporosis as Assessed Over 24 Months
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms MERIT-OP
- 08 Apr 2009 Planned number of patients changed from 1100 to 1231 as reported by ClinicalTrials.gov.
- 08 Apr 2009 Additional location identified as reported by ClinicalTrials.gov.
- 14 Jan 2008 Results published in Bone journal.